Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.
Circulating tumoral DNA (ctDNA), commonly named "liquid biopsy", has emerged as a new promising noninvasive tool to detect biomarker in several cancers including lung cancer. Applications involving molecular analysis of ctDNA in lung cancer have increased and encompass diagnosis, response to treatment, acquired resistance and prognosis prediction, while bypassing the problem of tumor heterogeneity. ctDNA may then help perform dynamic genetic surveillance in the era of precision medicine through indirect tumoral genomic information determination. The aims of this review were to examine the recent technical developments that allowed the detection of genetic alterations of ctDNA in lung cancer. Furthermore, we explored clinical applications in patients with lung cancer including treatment efficiency monitoring, acquired therapy resistance mechanisms and prognosis value.
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, 34295 Montpellier, France. J-vendrell@chu-montpellier.fr.
Julie A
JA
Vendrell
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, 34295 Montpellier, France. f-tran_mau_them@chu-montpellier.fr.
Frédéric Tran
FT
Mau-Them
IRCM, Institut de Recherche en Cancérologie de Montpellier, 34298 Montpellier, France. benoit.beganton@inserm.fr.|INSERM, U1194, 34298 Montpellier, France. benoit.beganton@inserm.fr.|ICM, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France. benoit.beganton@inserm.fr.|Université de Montpellier, 34000 Montpellier, France. benoit.beganton@inserm.fr.
Benoît
B
Béganton
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Microbiology, 34295 Montpellier, France. S-godreuil@chu-montpellier.fr.
Sylvain
S
Godreuil
IRCM, Institut de Recherche en Cancérologie de Montpellier, 34298 Montpellier, France. peter.coopman@inserm.fr.|INSERM, U1194, 34298 Montpellier, France. peter.coopman@inserm.fr.|ICM, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France. peter.coopman@inserm.fr.|Université de Montpellier, 34000 Montpellier, France. peter.coopman@inserm.fr.
Peter
P
Coopman
CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, 34295 Montpellier, France. j-solassol@chu-montpellier.fr.|IRCM, Institut de Recherche en Cancérologie de Montpellier, 34298 Montpellier, France. j-solassol@chu-montpellier.fr.|INSERM, U1194, 34298 Montpellier, France. j-solassol@chu-montpellier.fr.|Université de Montpellier, 34000 Montpellier, France. j-solassol@chu-montpellier.fr.
Jérôme
J
Solassol
D014408:Biomarkers, Tumor; D001706:Biopsy / Q000379:methods / Q000592:standards; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics*; D003955:Diagnostic Tests, Routine / Q000379:methods / Q000592:standards; D019468:Disease Management; D023281:Genomics / Q000379:methods; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D009360:Neoplastic Cells, Circulating / Q000378:metabolism* / Q000473:pathology; D016133:Polymerase Chain Reaction / Q000379:methods / Q000592:standards; D057285:Precision Medicine / Q000379:methods / Q000592:standards; D011379:Prognosis; D047368:Tumor Burden
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm
circulating DNA; lung cancer; molecular diagnosis; routine practice; targeted therapies